Inhibikase Therapeuticsの空売り状況は、投資家がInhibikase Therapeuticsの株価下落に賭けている度合いを知ることができます。空売りデータは2週間ごとに更新されます。

Inhibikase Therapeutics (NASDAQ:IKT) 株価情報, 空売り情報

Inhibikase Therapeutics

Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease ("PD"), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.

Inhibikase Therapeutics, Inc. - Common Stock

Inhibikase Therapeutics Inc

iTokk Inc

INTERTEK GROUP PLC ORD by Intertek Group Plc

Intertek Group PLC

INTERTEK GROUP UNSP/ADR by Intertek Group Plc

Macquarie analyst Tim Nollen maintains Unity Software (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/U#NYSE">U</a>) with a Underperform and raises the price target from $15 to $16.

News

Price Target

Analyst Ratings

Macquarie Maintains Underperform on Unity Software, Raises Price Target to $16

Macquarie analyst Tim Nollen maintains Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>) with a Outperform and raises the price target from $130 to $133.

Macquarie Maintains Outperform on Trade Desk, Raises Price Target to $133

Macquarie analyst Tim Nollen maintains Magnite (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MGNI#NASDAQ">MGNI</a>) with a Outperform and maintains $18 price target.

MGNI

Macquarie Maintains Outperform on Magnite, Maintains $18 Price Target

WIIM

REVB

Revelation Biosciences shares are trading higher after the company reported better-than-expected Q3 EPS results.

NPABU

Trading Halt: Halt status updated at 4:40:00 PM ET: Quotation Resumption: News and Resumption Times

NPAB

Trading Halt: Halt status updated at 4:35:00 PM ET: Quotation Resumption: News and Resumption Times

Earnings

Associated Cap Gr Q3 EPS $1.09

The second of three monthly contests in Benzinga's paper trading competition powered by TradeZero kicked off on Oct. 15, giving contestants a chance to take home a portion in the more than $30,000 in cash and prizes offered during&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">the three-month run.</a>
With one week left in the competition, the top of the leaderboard is close with new leaders emerging, including the first contest winner.
The Contests:&nbsp;Powered by&nbsp;TradeZero, the&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">World Championship of Trading</a>&nbsp;is the ultimate trading competition for investors to prove their keen eye during a three-month time period.
The first of three separate contests kicked off on Monday, Sept. 16. Over $5,000 in cash will be awarded to verified contest winners from the first contest.
With the first contest over, everyone who signs up for the second will now compete for the top prize of $10,000 in cash, a lifetime of Benzinga Pro Essential and a tour of the New York Stock Exchange with lunch for two at the exchange.
Contestants have until Nov. 7 to sign up for the second contest, with everyone starting over with a paper balance of $100,000. Based on the last contest&#8217;s results, investors may want to sign up and start trading today.
Each investor will have around one month across three separate contests to generate the highest profits from a starting balance of $100,000 in a simulated trading account.
Contestants in the World Championship of Trading will have access to Benzinga's Live Squawk product.
Investors will also gain exposure to TradeZero's newly patented short-selling tools.
Through Nov. 3 this is the current leaderboard for the second contest:
1st: Shruthi M.: $489,637.60
2nd: Andrea S.: $416,220.00
3rd: XiaoTian Z.: $302,710.00
Each of the top 10 contestants on the leaderboard has a balance of at least $197,290.00.
<a href="https://www.benzinga.com/exclusives/24/10/41666928/benzinga-world-championship-of-trading-powered-by-tradezero-top-trader-is-up-over-600-think-you-can">Last week's leader </a>XiaoTian Z. fell to third place. Shruthi M., who now leads the way, was in fourth place last week. The first contest winner Andrea S. has soared to second place after not being on the leaderboard last week.
This week's top 10 features only five of the top 10 from last week, which shows how the leaderboard changes. This means even if you missed the second contest deadline, you should have the upcoming contests on your radar, as anyone can win with some patience and good trades.
First Contest Winner:&nbsp;Andrea S., the winner of the first contest, went from $100,000 to more than $1 million in the paper trading account in&nbsp;<a href="https://www.benzinga.com/exclusives/24/10/41240862/benzinga-world-championship-of-trading-powered-by-tradezero-1-contestant-up-988-in-3-weeks-join-now" target="_blank" rel="noreferrer noopener">less than a month.</a>
Benzinga previously <a href="https://www.youtube.com/live/DjRmtokM2YQ?si=V0zxoFo4dHh0jPGT&amp;start=3615" target="_blank" rel="noreferrer noopener">interviewed </a>Andrea S., who was in the top 10 for most of the contest and was in first place several weeks.
Contest Rules:&nbsp;The contest is open to residents of the United States and Canada who are 21 years of age or older.
Traders will be able to buy simulated equities and options from U.S. markets during the contest periods starting with a balance of $100,000. No fractional shares will be allowed. Traders have to hold a minimum of one stock or option throughout the contest. A minimum of five days of one trade or more must be completed throughout each contest.
Interested investors have been able to&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">sign up to join</a>&nbsp;the contest since Friday, July 26. Signing up for the first contest will automatically register an entry in the second and third contests. Traders can sign up for the contests after the start dates as long as it is before a cutoff deadline.
The dates for the&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">contests</a>&nbsp;are listed below:
<ul>
<li>Contest 1: Sept. 15 through Oct. 14</li>
<li>Contest 2: Oct. 15 through Nov. 14</li>
<li>Contest 3: Nov. 15 through Dec. 14</li>
</ul>
The last days to register for the remaining contests are at 9 a.m. ET on Nov. 7 and Dec. 8.
Read Also:&nbsp;<a href="https://www.benzinga.com/fintech/23/11/35687369/tradezero-ceo-daniel-pipitone-giving-the-retail-traders-an-institutional-level-toolbox" target="_blank" rel="noreferrer noopener">TradeZero CEO Daniel Pipitone: Giving Retail Traders An Institutional-Level Toolbox</a>
Contest Prizes: Participants have the chance to win as much as $30,000 in cash and prizes during the contests. Travel and expenses will not be paid for the NYSE tour prizes.
Here are the prizes for the World Championship of Trading.
Contest 1:
<ul>
<li>First Place: $5,000 cash, lifetime of&nbsp;<a href="https://pro.benzinga.com/feature/newsfeed/?gspk=bHVrZWphY29iaTUzNDg&amp;gsxid=tdEE0VrK8Jeg&amp;ref=lukejacobi5348" target="_blank" rel="noreferrer noopener">Benzinga Pro Essential,</a>&nbsp;tour of the NYSE and lunch for two at the NYSE.</li>
<li>Second Place: $1,000 cash, one year of Benzinga Pro Essential.</li>
<li>Third Place: $500 cash, one year of Benzinga Pro Essential.</li>
</ul>
Contest 2:
<ul>
<li>First Place: $10,000 cash, lifetime of Benzinga Pro Essential, tour of the NYSE and lunch for two at the NYSE.</li>
<li>Second Place: $2,000 cash, one year of Benzinga Pro Essential.</li>
<li>Third Place: $1,000 cash, one year of Benzinga Pro Essential.</li>
</ul>
Contest 3:
<ul>
<li>First Place: $15,000 cash, lifetime of Benzinga Pro Essential, tour of the NYSE and lunch for two at the NYSE.</li>
</ul>
Find out more at the&nbsp;<a href="https://benzingapartners.go2cloud.org/aff_c?offer_id=467&amp;aff_id=1" target="_blank" rel="noreferrer noopener">World Championship of Trading site</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/top-stories/24/11/41718416/exclusive-top-20-most-searched-tickers-on-benzinga-pro-in-october-2024-where-do-tesla-nvidia-apple-d">EXCLUSIVE: Top 20 Most-Searched Tickers On Benzinga Pro In October 2024 — Where Do Tesla, Nvidia, Apple, DJT Stock Rank?</a></li>
</ul>
The World Championship of Trading (the "Contest") involves the assembling and managing of a fantasy stock portfolio and not actual trading results. Contest information and results (collectively, the &#8220;Content&#8221;) have been made available for information and entertainment purposes only and should not be considered trading or investment advice or a recommendation as to any security. All trading involves risks. Neither Benzinga nor TradeZero make any representations and warranties with respect to the accuracy of the Content, nor do they accept any liability which may arise directly or indirectly from use of the Content. See the&nbsp;<a href="https://tradezeroedge.com/world-championship-of-trading/contest-instructions" target="_blank" rel="noreferrer noopener">Contest's official rules</a>&nbsp;for all terms and conditions. TradeZero provides self-directed brokerage accounts to customers through its operating affiliates: TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas; and TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of the Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF). If you have any specific questions about TradeZero&#8217;s brokerage services, please reach out to the TradeZero broker dealer in your jurisdiction.

Exclusives

Benzinga World Championship Of Trading Powered By TradeZero Top Trader Is Up Over 400% In Second Contest, First Contest Winner Ranks Second

Management

RDUS

Radius Recycling Appoints Marc Hathhorn As COO

Macquarie analyst Aaron Lee maintains Playtika Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTK#NASDAQ">PLTK</a>) with a Neutral and maintains $7 price target.

PLTK

Macquarie Maintains Neutral on Playtika Holding, Maintains $7 Price Target

OPOF

Old Point Financial Corporation Appoints Cathy W. Liles As CFO

Macquarie analyst Aaron Lee maintains Corsair Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSR#NASDAQ">CRSR</a>) with a Outperform and lowers the price target from $11 to $9.

CRSR

Macquarie Maintains Outperform on Corsair Gaming, Lowers Price Target to $9

Tredegar Q3 EPS From Ongoing Operations $0.01, Sales $182M Up From $166.19M YoY

Macquarie analyst Ross Compton maintains Klaviyo (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KVYO#NYSE">KVYO</a>) with a Neutral and maintains $36 price target.

KVYO

Macquarie Maintains Neutral on Klaviyo, Maintains $36 Price Target

Across the recent three months, 5 analysts have shared their insights on Coeur Mining (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CDE#NYSE">CDE</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $7.95, a high estimate of $8.50, and a low estimate of $7.00. Surpassing the previous average price target of $7.55, the current average has increased by 5.3%.
<img src="https://www.benzinga.com/files/images/story/2024/1731100849_0.png" alt="price target chart" />
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
A clear picture of Coeur Mining's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joe Reagor</td>
<td>Roth MKM</td>
<td>Lowers</td>
<td>Buy</td>
<td>$8.50</td>
<td>$9.00</td>
</tr>
<tr>
<td>Dalton Baretto</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$7.75</td>
<td>$7.00</td>
</tr>
<tr>
<td>Joe Reagor</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$8.50</td>
<td>$8.00</td>
</tr>
<tr>
<td>Kevin O'Halloran</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$8.00</td>
<td>$7.50</td>
</tr>
<tr>
<td>Brian MacArthur</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$7.00</td>
<td>$6.25</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Coeur Mining. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Coeur Mining compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Coeur Mining's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
For valuable insights into Coeur Mining's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/CDE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Coeur Mining analyst ratings.</a>
<h2>About Coeur Mining</h2>
Coeur Mining Inc is a metals producer focused on mining precious minerals in the Americas. It is involved in the discovery and mining of gold and silver and generates the vast majority of revenue from the sale of these precious metals. The operating mines of the company are palmarejo, Rochester, Wharf, and Kensington. Its projects are located in the United States, Canada Mexico, and North America.
<h3>Key Indicators: Coeur Mining's Financial Health</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Positive Revenue Trend: Examining Coeur Mining's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of 61.1% as of 30 September, 2024, showcasing a substantial increase in top-line earnings. When compared to others in the Materials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Coeur Mining's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of 15.55%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Coeur Mining's ROE stands out, surpassing industry averages. With an impressive ROE of 4.61%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Coeur Mining's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.23%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 0.56, Coeur Mining faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What 5 Analyst Ratings Have To Say About Coeur Mining

4 analysts have shared their evaluations of AAON (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAON#NASDAQ">AAON</a>) during the recent three months, expressing a mix of bullish and bearish perspectives.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated AAON and provided 12-month price targets. The average target is $132.25, accompanied by a high estimate of $150.00 and a low estimate of $111.00. Witnessing a positive shift, the current average has risen by 14.67% from the previous average price target of $115.33.
<img src="https://www.benzinga.com/files/images/story/2024/1731100831_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of AAON among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brent Thielman</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$150.00</td>
<td>$102.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$138.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$130.00</td>
<td>$114.00</td>
</tr>
<tr>
<td>Julio Romero</td>
<td>Sidoti &amp; Co.</td>
<td>Announces</td>
<td>Neutral</td>
<td>$111.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to AAON. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of AAON compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for AAON's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of AAON's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/AAON/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on AAON analyst ratings.</a>
<h2>Discovering AAON: A Closer Look</h2>
AAON Inc is a manufacturer of air-conditioning and heating equipment. The products include rooftop units, chillers, packaged outdoor mechanical rooms, air-handling units, makeup air units, energy-recovery units, condensing units, geothermal heat pumps, and self-contained units and coils. AAON's products serve the commercial and industrial new construction and replacement markets, primarily in North America.
<h3>A Deep Dive into AAON's Financials</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: AAON's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 10.43%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Industrials sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: AAON's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 16.66% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 6.85%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 5.32%, the company showcases effective utilization of assets.
Debt Management: AAON's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.14.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AAON

The Analyst Landscape: 4 Takes On AAON

In the latest quarter, 15 analysts provided ratings for Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>), showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">10</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">3</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $55.4, a high estimate of $66.00, and a low estimate of $40.00. This upward trend is apparent, with the current average reflecting a 8.48% increase from the previous average price target of $51.07.
<img src="https://www.benzinga.com/files/images/story/2024/1731100784_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Tapestry. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Rick Patel</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$57.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Mark Altschwager</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$58.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Oliver Chen</td>
<td>TD Cowen</td>
<td>Maintains</td>
<td>Hold</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Paul Lejuez</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$55.00</td>
<td>$49.00</td>
</tr>
<tr>
<td>Michael Binetti</td>
<td>Evercore ISI Group</td>
<td>Raises</td>
<td>Outperform</td>
<td>$63.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Lorraine Hutchinson</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$60.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$66.00</td>
<td>$51.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Brooke Roach</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$52.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Jay Sole</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Ike Boruchow</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Matthew Boss</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Dana Telsey</td>
<td>Telsey Advisory Group</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$54.00</td>
<td>$54.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Tapestry. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Tapestry compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Tapestry's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Tapestry's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TPR/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Tapestry analyst ratings.</a>
<h2>All You Need to Know About Tapestry</h2>
Coach, Kate Spade, and Stuart Weitzman are Tapestry's fashion and accessory brands. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (64% of fiscal 2024 sales), Europe, Asia (29% of fiscal 2024 sales), and elsewhere. Coach (76% of fiscal 2024 sales) is best known for affordable luxury leather products. Kate Spade (20% of fiscal 2023 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2024. Stuart Weitzman (4% of sales) generates virtually all its revenue from women's footwear.
<h3>Unraveling the Financial Story of Tapestry</h3>
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Tapestry's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -1.75%. This indicates a decrease in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Consumer Discretionary sector.
Net Margin: Tapestry's net margin is impressive, surpassing industry averages. With a net margin of 10.01%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Tapestry's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 5.62%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Tapestry's ROA excels beyond industry benchmarks, reaching 1.17%. This signifies efficient management of assets and strong financial health.
Debt Management: Tapestry's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 3.03.
<h2>How Are Analyst Ratings Determined?</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Critical Insights From Tapestry Analyst Ratings: What You Need To Know

Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(2.84) by 70.42 percent.

Earnings Beats

Revelation Biosciences Q3 2024 GAAP EPS $(0.84) Beats $(2.84) Estimate

Analysts' ratings for Lumentum Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LITE#NASDAQ">LITE</a>) over the last quarter vary from bullish to bearish, as provided by 15 analysts.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $66.87, a high estimate of $115.00, and a low estimate of $40.00. This upward trend is apparent, with the current average reflecting a 19.69% increase from the previous average price target of $55.87.
<img src="https://www.benzinga.com/files/images/story/2024/1731100743_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Lumentum Holdings among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tim Savageaux</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$60.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Simon Leopold</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$100.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$115.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Christopher Rolland</td>
<td>Susquehanna</td>
<td>Raises</td>
<td>Positive</td>
<td>$80.00</td>
<td>$70.00</td>
</tr>
<tr>
<td>Simon Leopold</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$70.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Tim Savageaux</td>
<td>Northland Capital Markets</td>
<td>Raises</td>
<td>Market Perform</td>
<td>$45.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Vivek Arya</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$50.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>George Notter</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$65.00</td>
<td>$53.00</td>
</tr>
<tr>
<td>Richard Shannon</td>
<td>Craig-Hallum</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Meta Marshall</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$54.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Tom O'Malley</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$40.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Dave Kang</td>
<td>B. Riley Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$50.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Mike Genovese</td>
<td>Rosenblatt</td>
<td>Raises</td>
<td>Buy</td>
<td>$69.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Alex Henderson</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$70.00</td>
<td>$65.00</td>
</tr>
<tr>
<td>Samik Chatterjee</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$65.00</td>
<td>$57.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Lumentum Holdings. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Offering a comprehensive view, analysts assess stocks qualitatively, spanning from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Lumentum Holdings compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Lumentum Holdings's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Lumentum Holdings's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/LITE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Lumentum Holdings analyst ratings.</a>
<h2>Discovering Lumentum Holdings: A Closer Look</h2>
Lumentum Holdings Inc is a California-based technology firm. The company provides two types of optical and photonic products: optical components that are used in telecommunications networking equipment, and commercial lasers for manufacturing, inspection, and life-science lab uses. Its segments are Optical Communications and Commercial Lasers. The firm is also expanding into new optical applications, such as 3-D sensing laser diode for consumer electronics. It generates maximum revenue from the OpComms segment. The OpComms segment products include a wide range of components, modules, and subsystems to support customers including carrier networks for access (local), metro (intracity), long-haul, and submarine (undersea) applications.
<h3>Lumentum Holdings: Financial Performance Dissected</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Lumentum Holdings's financials over 3 months reveals challenges. As of 30 June, 2024, the company experienced a decline of approximately -16.86% in revenue growth, reflecting a decrease in top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Information Technology sector.
Net Margin: Lumentum Holdings's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -81.9%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of -23.66%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Lumentum Holdings's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of -6.21%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Lumentum Holdings's debt-to-equity ratio stands notably higher than the industry average, reaching 2.67. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<h2>Understanding the Relevance of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

LITE

In-Depth Examination Of 15 Analyst Recommendations For Lumentum Holdings

Providing a diverse range of perspectives from bullish to bearish, 13 analysts have published ratings on Cheesecake Factory (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAKE#NASDAQ">CAKE</a>) in the last three months.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">5</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">4</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">1</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $46.69, a high estimate of $52.00, and a low estimate of $36.00. This upward trend is evident, with the current average reflecting a 7.23% increase from the previous average price target of $43.54.
<img src="https://www.benzinga.com/files/images/story/2024/1731100718_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Cheesecake Factory. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$52.00</td>
</tr>
<tr>
<td>Katherine Griffin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$49.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Zachary Fadem</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$45.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$44.00</td>
<td>$38.00</td>
</tr>
<tr>
<td>David Tarantino</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Raises</td>
<td>Outperform</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Raises</td>
<td>Overweight</td>
<td>$51.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Dennis Geiger</td>
<td>UBS</td>
<td>Raises</td>
<td>Sell</td>
<td>$36.00</td>
<td>$32.00</td>
</tr>
<tr>
<td>Katherine Griffin</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jeffrey Bernstein</td>
<td>Barclays</td>
<td>Raises</td>
<td>Underweight</td>
<td>$38.00</td>
<td>$35.00</td>
</tr>
<tr>
<td>Jim Salera</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Nick Setyan</td>
<td>Wedbush</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Jon Tower</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$51.00</td>
<td>$46.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Cheesecake Factory. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Cheesecake Factory compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of Cheesecake Factory's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Cheesecake Factory's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CAKE/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Cheesecake Factory analyst ratings.</a>
<h2>Get to Know Cheesecake Factory Better</h2>
Cheesecake Factory Inc owns and operates restaurants in the United States and Canada under brands that include The Cheesecake Factory, North Italia, and a collection within the Fox Restaurants Concepts subsidiary. The company's international presence, in the Middle East and Mexico, is through licensing agreements with third parties. The company also has a bakery division that produces cheesecakes and other baked products for sale in its restaurants, international licensees, and third-party bakery customers. The company has four operating business segments: The Cheesecake Factory restaurants, North Italia, other FRC, and Flower Child. Majority of the company's revenue comes from The Cheesecake Factory restaurants segment.
<h3>Unraveling the Financial Story of Cheesecake Factory</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Cheesecake Factory's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 4.25%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of 3.47%, the company may need to address challenges in effective cost control.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 7.79%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): Cheesecake Factory's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 1.03%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 4.76, Cheesecake Factory adopts a prudent financial strategy, indicating a balanced approach to debt management.
<h2>Analyst Ratings: What Are They?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CAKE

A Closer Look at 13 Analyst Recommendations For Cheesecake Factory

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Inhibikase Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/ikt-stock-quote/">IKT</a>) just reported results for the second quarter of 2024.<ul><li>Inhibikase Therapeutics reported earnings per share of -66 cents. This was above the analyst estimate for EPS of -67 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/ikt-stock-earnings-inhibikase-therapeutics-for-q2-of-2024/">IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

IKT Stock Earnings: Inhibikase Therapeutics Beats EPS for Q2 2024

Inhibikase Therapeutics GAAP EPS of -$0.66 beats by $0.01

Inhibikase Therapeutics, Inc. (IKT) Q2 2024 Earnings Call Transcript

Inhibikase Therapeutics ( ($IKT) ) has provided an announcement. Inhibikase Therapeutics, Inc. released a new presentation on their website detaili...

Inhibikase Therapeutics Unveils PAH and Parkinson's Drug Pipeline

Inhibikase Therapeutics stock rises after pricing $110M private offering

Inhibikase Therapeutics ( ($IKT) ) has shared an update. Inhibikase Therapeutics, Inc. has entered into an agreement for a private placement transa...

Inhibikase Therapeutics Secures $110M for Drug Development

Inhibikase Therapeutics (IKT) announced the closing of a private placement of approximately $110 Million from the issuance and sale of shares of th...

Inhibikase Therapeutics closes up to $275M financing, advances IkT-001Pro

Inhibikase Therapeutics ( ($IKT) ) has shared an update. Inhibikase Therapeutics, Inc. has secured approximately $110 million through a private pla...

Inhibikase Therapeutics Secures Funding and Strengthens Leadership

Jefferies initiated coverage of Inhibikase Therapeutics (IKT) with a Buy rating and $8 price target The stock looks inexpensive as its novel imatin...

Inhibikase Therapeutics initiated with a Buy at Jefferies

Inhibikase Therapeutics (IKT) has received a new Buy rating, initiated by Jefferies analyst, Dennis Ding. Dennis Ding has given his Buy rating due ...

Inhibikase Therapeutics: Promising PAH Market Potential and Strategic Advancements Justify Buy Rating

Health Care

Press Releases

Inhibikase Therapeutics Announces Final Pre-IND Meeting Outcomes for IkT-001Pro as a Treatment for Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Request for Withdrawal of S-1 Registration Statement

Inhibikase Therapeutics Reports First Quarter Financial Results and Highlights Recent Period Activity

Inhibikase Therapeutics Announces Pricing of Registered Direct Offering and Warrant Inducement, Priced At-The-Market for Aggregate Gross Proceeds of $4.0 Million

Inhibikase Therapeutics Announces Expansion to its Therapeutic Pipeline and Updates its Research and Development Programs

Inhibikase Therapeutics Completes Enrollment of the Phase 2 '201' Trial Evaluating Risvodetinib in Untreated Parkinson's Disease

Inhibikase Therapeutics to Report Second Quarter 2024 Financial Results on August 14, 2024

Inhibikase Therapeutics Reports Second Quarter Financial Results and Highlights Recent Period Activity

General

Inhibikase Therapeutics Announces Pricing of $110 Million Private Placement to Advance IkT-001Pro, an Optimized Prodrug of Imatinib, into a Late-Stage Trial in Pulmonary Arterial Hypertension

Inhibikase Therapeutics Announces Closing of up to $275 Million Financing and Advancement of IkT-001Pro into a Late Stage Clinical Trial in Pulmonary Arterial Hypertension

Acumen Pharmaceuticals, Inc. - Common Stock

Acumen Pharmaceuticals

Achieve Life Sciences, Inc. - Common Shares

Achieve Life Sciences

Actuate Therapeutics, Inc. - Common stock

Actuate Therapeutics

Adaptimmune Therapeutics plc - American Depositary Shares

Adaptimmune Therapeutics

Adverum Biotechnologies, Inc. - Common Stock

Adverum Biotechnologies

Atossa Therapeutics

Black Diamond Therapeutics, Inc. - Common Stock

Black Diamond Therapeutic

Candel Therapeutics

CAMP4 Therapeutics Corporation - Common Stock

Camp4 Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

Cardiff Oncology

Galectin Therapeutics Inc. - Common Stock

Galectin Therapeutics

Greenwich LifeSciences, Inc. - Common stock

Greenwich LifeSciences

Gossamer Bio

Kazia Therapeutics Limited - American Depositary Shares

Kazia Therapeutics

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Nanobiotix

Nuvectis Pharma

PepGen

Sagimet Biosciences Inc. - Series A Common Stock

Comments

Inhibikase Therapeutics

空売り

Inhibikase Therapeutics (NASDAQ:IKT) 株価情報, 空売り情報

こんな人も見ています

ニュース

パートナーシップ

ベンジンガ・グローバル